Physician profile
Risa B Ross
NPI 1891943775
$11,550.50
in general payments reported to CMS, 2019-2025
37 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $701 · 2021: $1,141 · 2022: $2,031 · 2023: $2,405 · 2024: $2,200 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,448 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,447.63 |
| Education | $160.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,703.97 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $955.26 | 2019-2025 | |
| Janssen Biotech, INC. | $826.65 | 2020-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $730.37 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $630.21 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $586.31 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $556.46 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Genzyme Corporation | $548.92 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $537.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $534.99 | 2019-2025 | |
| Galderma Laboratories, L.P. | $528.03 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $429.35 | 2019-2025 | Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $409.01 | 2022-2025 | Sotyktu |
| Ucb, INC. | $334.77 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $333.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $287.29 | 2019-2024 | Seysara |
| Incyte Corporation | $273.45 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $256.10 | 2020-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $186.63 | 2022-2024 | Vtama |
| Smith+Nephew, INC. | $143.22 | 2023 | Grafix |
| Biofrontera INC. | $129.80 | 2021-2022 | |
| Journey Medical Corporation | $103.00 | 2019-2025 | |
| Organogenesis INC. | $93.31 | 2023-2024 | Puraply, Affinity |
| Vyne Pharmaceuticals INC. | $67.14 | 2020-2021 | |
| Botanix Sb INC | $57.97 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $45.36 | 2022 | |
| Verrica Pharmaceuticals INC. | $45.21 | 2023-2025 | Ycanth |
| Celgene Corporation | $39.01 | 2019 | |
| Aclaris Therapeutics, INC. | $38.83 | 2019 | |
| Epi Health, LLC | $22.94 | 2022 | |
| Organon LLC | $22.34 | 2025 | Vtama |
| Dermira, INC. | $20.56 | 2019 | |
| Encore Dermatology INC. | $19.44 | 2019 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.72 | 2023 | Nuzyra |
| Medela LLC | $13.03 | 2019 | |
| Nabriva Therapeutics, Plc | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Risa Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.